Amgen Licenses Astellas-Partnered AMG 337 To NantPharma
This article was originally published in Scrip
NantPharma LLC, a subsidiary of Patrick Soon-Shiong's NantWorks LLC empire, licensed AMG 337 outside of Japan, Russia and other central Asian countries from Amgen Inc., which previously partnered with Astellas Pharma Inc. to develop the cancer drug and four other compounds in certain Asia territories.
You may also be interested in...
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.